These compounds resulted in down-regulation of the DNMT enzymes in the breast cancer cells but not in the MCF-10A cells, thus RES appeared to target SIRT1 specifically in breast cancer but not in normal cells [9]. The gene discussed is SIRT1; the disease is breast cancer.